Oxford Biomedica (LON:OXB) Price Target Cut to GBX 1,140 by Analysts at Royal Bank Of Canada

Oxford Biomedica (LON:OXB) had its price target cut by research analysts at Royal Bank Of Canada from GBX 1,170 to GBX 1,140 in a research note issued to investors on Wednesday,Digital Look reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price points to a potential upside of 85.37% from the company’s current price.

Several other research analysts have also commented on the stock. Stifel Nicolaus restated a “buy” rating and issued a GBX 950 price objective on shares of Oxford Biomedica in a report on Wednesday, March 11th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Oxford Biomedica presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 600.04.

Oxford Biomedica Price Performance

OXB opened at GBX 615 on Wednesday. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. The stock has a market capitalization of £744.21 million, a PE ratio of -22.85 and a beta of 1.10. The stock’s 50 day moving average price is GBX 614.79 and its 200-day moving average price is GBX 663.15. Oxford Biomedica has a 52-week low of GBX 306 and a 52-week high of GBX 952.

Oxford Biomedica (LON:OXB) last announced its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. On average, equities research analysts predict that Oxford Biomedica will post -31.0799998 EPS for the current year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.